• Home
  • About Us
  • Contact
  • Subscribe
  • Your Account
  • Login
No Result
View All Result
Friday, June 2, 2023
Alternatives Watch
  • Home
  • Hedge Funds
    • Manager News
    • Mandates
    • Service Provider News
    • CTAs/Managed Futures
  • Private Equity
    • Manager News
    • Mandates
    • Service Provider News
  • Private Credit
    • Manager News
    • Mandates
    • Service Provider News
  • RE/Infrastructure
    • Manager News
    • Mandates
    • Service Provider News
  • Investor News
    • Endowments and Foundations
    • ESG
    • Pensions
    • Platforms
    • Consultants
  • Research
    • Investor Scorecard
    • Manager Scorecard
  • Subscribe
  • Home
  • Hedge Funds
    • Manager News
    • Mandates
    • Service Provider News
    • CTAs/Managed Futures
  • Private Equity
    • Manager News
    • Mandates
    • Service Provider News
  • Private Credit
    • Manager News
    • Mandates
    • Service Provider News
  • RE/Infrastructure
    • Manager News
    • Mandates
    • Service Provider News
  • Investor News
    • Endowments and Foundations
    • ESG
    • Pensions
    • Platforms
    • Consultants
  • Research
    • Investor Scorecard
    • Manager Scorecard
  • Subscribe
No Result
View All Result
Alternatives Watch
No Result
View All Result

NovaQuest backs German pharma’s osteoarthritis treatment

Sergio BarretobySergio Barreto
April 5, 2022
in Manager News, Private Equity
Novaquest backs German biotech’s osteoarthritis treatment

By twenty20photos/Envato Elements

ShareTweetShareSendSend

NovaQuest Capital Management expanded is royalty pipeline with a deal to support development of German pharmaceutical firm Grünenthal’s lead asset, the osteoarthritis product candidate resiniferatoxin (RTX).

Under the newly announced deal, NovaQuest will reimburse Grünenthal’s investments into late-stage studies of RTX and share the clinical development and approval risks with Grünenthal. If RTX receives marketing approval, NovaQuest will receive one-time payments or milestones and revenue-based payments over the course of the drug’s commercialization.

RTX is an injectable drug being developed as a non-opioid treatment option for pain relief in patients with advanced knee osteoarthritis. RTX works by inhibiting of Transient Receptor Potential Vanilloid 1, a chemical expressed on sensory neurons, providing long-lasting relief and functional improvement of the affected joints.

“Globally, more than 300 million patients suffer from osteoarthritis,” said Grünenthal Chief Scientific Officer Jan Adam. “For many of them, the available treatment options are not sufficient and they may at some point in time experience severe symptoms including pain.”

The funding provided by the deal will enable Grünenthal to advance RTX into Phase III trials to assess the efficacy, safety and tolerability of RTX. The trials are expected to begin this year and are designed to meet the requirements for marketing approval in the EU, the U.S., and Japan.

The osteoarthritis treatment market across the seven major markets of the U.S., France, Germany, Italy, Spain, the UK and Japan, is forecast to see a compound annual growth rate of 17.8% from 2014 to 2024, more than tripling in value from $3.25 billion to $10.49 billion, according to GlobalData.

Grünenthal, a privately-held firm based in Aachen, Germany, estimates potential peak sales for RTX to be above €1 billion in Europe and the U.S. for the treatment of knee osteoarthritis alone, but the company also aims to explore the potential of RTX for the treatment of osteoarthritis-related pain in additional joints beyond the knee.

“NovaQuest is excited to partner with the leading company in the therapeutic area of pain to develop RTX, a promising asset that may enter the market as soon as 2025,” said Ryan Wooten, Managing Director at NovaQuest. “We are confident that Grünenthal has the right capabilities in place to position RTX on the global osteoarthritis market and leverage the full potential of the asset for patients in need.”

NovaQuest Founding Partner and CIO Jonathan Tunnicliffe recently discussed the firm’s healthcare-focused investment approach with us. Check it out below.

NovaQuest finds value in drug commercialization
Tags: EuropeGermanyLife SciencesNovaQuest
ShareTweetShareSendSend
Previous Post

Franklin Templeton adds PE secondaries business

Next Post

Blue Wolf raises over $1bn for new fund

Related Posts

People moves in the alternative investments industry
Consultants

People moves for week of June 2

Mass PRIM adds $640m to diverse PE strategies
Pensions

Mass PRIM adds $640m to diverse PE strategies

Adams Street sees strong secondaries demand with $3.2bn fund close
Private Equity

Adams Street sees strong secondaries demand with $3.2bn fund close

IMRF approves $315m in new commitments
Pensions

IMRF approves $315m in new commitments

Ohio pension adds PE, credit funds
Pensions

Ohio pension adds PE, credit funds

Next Post
Blue Wolf raises over $1bn for new fund

Blue Wolf raises over $1bn for new fund

Log In/Out

Lost your password?

Search the AW Archives

No Result
View All Result

Recent News

People moves in the alternative investments industry

People moves for week of June 2

Activist investor Jana Partners escalates Freshpet battle with court filing

Activist investor Jana Partners escalates Freshpet battle with court filing

Rockhampton shuts pan-Asia fund

Rockhampton shuts pan-Asia fund

Millennium hires ex-Balyasny analyst Starikovsky as senior PM

Millennium hires ex-Balyasny analyst Starikovsky as senior PM

Be an Alts Insider

Sign up for your FREE daily alts news briefing

Subscribe

Subscribe to AW
Alternatives Watch

© 2019-2022, All Rights Reserved  |  BMV Digital

Navigate Site

  • Investor News
  • Private Equity
  • Private Credit
  • Hedge Funds
  • Real Estate/Infrastructure
  • Subscribe
  • Your Membership
  • Terms of Service
  • Privacy Policy

Follow Us

No Result
View All Result
  • Home
  • Hedge Funds
    • Manager News
    • Mandates
    • Service Provider News
    • CTAs/Managed Futures
  • Private Equity
    • Manager News
    • Mandates
    • Service Provider News
  • Private Credit
    • Manager News
    • Mandates
    • Service Provider News
  • RE/Infrastructure
    • Manager News
    • Mandates
    • Service Provider News
  • Investor News
    • Endowments and Foundations
    • ESG
    • Pensions
    • Platforms
    • Consultants
  • Research
    • Investor Scorecard
    • Manager Scorecard
  • Subscribe

© 2019-2022, All Rights Reserved  |  BMV Digital

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Be an alts insider

Start your days in the know with our free newsletter

No, I don't want to be an alts insider

Thank

You!

Follow us
on LinkedIn

Lost your password?

This Website Uses Cookies
We use cookies on our website to provide necessary functions. By clicking “Accept”, you consent to the use of all strictly necessary cookies.
Do not sell my personal information.
Cookie Settings Accept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Save & Accept
Powered by CookieYes Logo